Our previous sequential CD19-22-20 CAR-T cell therapies demonstrated 41.7% overall CR rate in 17 pediatric patients with r/r B-cell lymphoma, including 13 BL (9). The gene discussed is CD19; the disease is Burkitt lymphoma.